Pharmaceutical News

RSS

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the first findings from Company research aimed at optimizing the dosing of its IMGN853 product candidate.

9 Apr 2014

Researchers identify novel compound effective against drug-resistant lung cancer

Despite advances made in detecting and treating nonsmall cell lung cancer, its prognosis remains grim. Even patients whose cancers are caught at their earliest stage have only a 50 percent chance of five-year survival. This poor prognosis is due in part to the cancer's ability to resist treatment, rendering the chemotherapy ineffective.

9 Apr 2014

Production of Immutep’s ImmuFact IMP321 starts at WuXi AppTec facilities in China

Immutep S.A., the biopharmaceutical company specializing in immuno-oncology, and Eddingpharm have started production of Immutep’s ImmuFact IMP321 (a LAG-3Ig fusion protein) at WuXi AppTec facilities in China. The product is being produced to European, U.S. and Chinese GMP standards.

8 Apr 2014

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Janssen Research & Development, LLC ("Janssen") today announced the submission of a supplemental New Drug Application (sNDA) for IMBRUVICA™ (ibrutinib) to the U.S. Food and Drug Administration (FDA) by its collaboration partner Pharmacyclics, Inc.

8 Apr 2014

Access provides update on new formulation of anti-inflammatory drug amlexanox

ACCESS PHARMACEUTICALS, INC. (OTCBB: ACCP) provided an update on a new formulation of the anti-inflammatory drug amlexanox, called LexaGard™, for the treatment of inflammatory and ulcerative conditions of the esophagus.

8 Apr 2014

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar") today announced the presentation of new data in a poster entitled, "In vivo efficacy of VAL-083 in the treatment of non-small cell lung cancer." DelMar's data was presented on Sunday, April 6, 2014 during the Novel Cytotoxic Strategies Session at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego.

8 Apr 2014

SLU researcher receives NIH grant to study on type of opioids that lead to depression

After finding a link between chronic use of prescription-based painkillers and increase in risk of depression, Saint Louis University researcher Jeffrey Scherrer, Ph.D., has received a $391,706 NIH grant to further investigate the pattern in a wider patient base, and study the type of opioids that lead to depression.

8 Apr 2014

TSRI reveals new aspects of more potent anti-diabetic drugs with fewer serious side effects

8 Apr 2014

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Pradaxa® (dabigatran etexilate mesylate) for the treatment of deep venous thrombosis (DVT) and pulmonary embolism (PE) in patients who have been treated with a parenteral anticoagulant for five to 10 days, and to reduce the risk of recurrent DVT and PE in patients who have been previously treated. DVT and PE are collectively referred to as venous thromboembolism (VTE).

8 Apr 2014

Professor receives $1.7M NIH grant to explore novel treatments for chronic methamphetamine users

A Wayne State University professor recently received a nearly $1.7 million grant from the National Institutes of Drug Abuse of the National Institutes of Health to explore whether proteasome and parkin — two components of the ubiquitin-proteasome system — are potential pharmaceutical drug targets that can be manipulated to promote survival and recovery of dopaminergic terminals after binge and chronic administration of toxic doses of methamphetamine.

8 Apr 2014

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

The German Institute for Quality and Efficiency in Health Care (IQWiG) reassessed the antiviral drug combination rilpivirine/emtricitabine/tenofovir. In early 2012, the combination was approved for the treatment of adults infected with human immunodeficiency virus type 1 (HIV-1) who have not received previous antiretroviral treatment.

8 Apr 2014

Findings could lead to more potent anti-diabetic drugs with fewer side effects

Scientists thought they basically knew how the most common drugs used to treat type 2 diabetes worked, but a new study from the Florida campus of The Scripps Research Institute (TSRI) reveals unexpected new aspects of the process. These findings could eventually lead to more potent anti-diabetic drugs with fewer serious side effects.

7 Apr 2014

Low-dose aspirin not significantly associated with pregnancy loss

The Effects of Aspirin in Gestation and Reproduction (EAGeR) medical trial has found that, in general, low-dose aspirin is not beneficial for future pregnancy outcomes in women with prior pregnancy loss.

7 Apr 2014

Head and neck cancers associated with genetic alterations could be sensitive to existing cancer drug

An examination of the genetic landscape of head and neck cancers indicates that while metastatic and primary tumor cells share similar mutations, recurrent disease is associated with gene alterations that could be exquisitely sensitive to an existing cancer drug.

7 Apr 2014

Treatment for opioid overdose now available for use by non-medical personnel

The U.S. Food and Drug Administration (FDA) has approved the first naloxone treatment specifically designed to be given by family members or caregivers to treat a person with opioid overdose.

4 Apr 2014

FDA approves expanded use Dyax’s KALBITOR in treatment of acute hereditary angioedema

Dyax Corp. today announced that the U.S. Food and Drug Administration (FDA) has approved an expansion of the indication for KALBITOR (ecallantide), a peptide inhibitor of plasma kallikrein used in the treatment of acute hereditary angioedema (HAE) attacks, to include patients 12 years of age and older.

4 Apr 2014

Study reveals role of dopamine in hippocampus region of brain

Bruno Giros, PhD, a researcher at the Douglas Mental Health University Institute and a professor in the Department of Psychiatry at McGill University, has demonstrated, for the first time, the role that dopamine plays in a region of the brain called the hippocampus.

4 Apr 2014

Pharmaceutical News

ImmunoGen presents first findings aimed at optimizing dosage of IMGN853 product candidate

Researchers identify novel compound effective against drug-resistant lung cancer

Production of Immutep’s ImmuFact IMP321 starts at WuXi AppTec facilities in China

Janssen submits supplemental New Drug Application for IMBRUVICA to the U.S. FDA

Access provides update on new formulation of anti-inflammatory drug amlexanox

DelMar presents pre-clinical study data that evaluates activity of VAL-083 in drug-resistant NSCLC

SLU researcher receives NIH grant to study on type of opioids that lead to depression

TSRI reveals new aspects of more potent anti-diabetic drugs with fewer serious side effects

Pradaxa receives FDA approval for treatment and reduction of risk of recurrence of DVT and PE

Professor receives $1.7M NIH grant to explore novel treatments for chronic methamphetamine users

Added benefit of antiviral drug combination in treatment of HIV-1 patients is not proven

Findings could lead to more potent anti-diabetic drugs with fewer side effects

Low-dose aspirin not significantly associated with pregnancy loss

Head and neck cancers associated with genetic alterations could be sensitive to existing cancer drug

Treatment for opioid overdose now available for use by non-medical personnel

FDA approves expanded use Dyax’s KALBITOR in treatment of acute hereditary angioedema

Study reveals role of dopamine in hippocampus region of brain

FDA clears Omeros' OMS721 IND for inhibition of complement‑mediated TMAs

Europe's pharmaceutical research community to convene at PRO & eCOA Congress

Patients' risk of stroke increases following shingles, but antiviral drugs appear to offer protection

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News